BFG
DGX icon

Bleakley Financial Group’s Quest Diagnostics DGX Stock Holding History

Bleakley Financial Group’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,559
Closed -$2.07M – 954
2026
Q1 		$2.07M Buy
+10,559
New +$2.05M 0.03% 382
2025
Q1 		– Sell
-2,078
Closed -$313K – 624
2024
Q4 		$313K Buy
2,078
+94
+5% +$14.6K 0.01% 785
2024
Q3 		$308K Buy
1,984
+46
+2% +$6.87K 0.01% 762
2024
Q2 		$265K Buy
1,938
+98
+5% +$13.4K 0.01% 794
2024
Q1 		$245K Sell
1,840
-251
-12% -$32.6K 0.01% 823
2023
Q4 		$288K Buy
2,091
+244
+13% +$32.1K 0.01% 749
2023
Q3 		$225K Sell
1,847
-118
-6% -$15.7K 0.01% 768
2023
Q2 		$276K Buy
1,965
+30
+2% +$4.14K 0.01% 747
2023
Q1 		$274K Sell
1,935
-206
-10% -$29.5K 0.01% 734
2022
Q4 		$335K Buy
+2,141
New +$308K 0.01% 668

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Bleakley Financial Group's DGX Position: Q2 2026 in Review

Bleakley Financial Group sold out of Quest Diagnostics (DGX) in Q2 2026, closing a stake of 10,559 shares — an estimated $2.07M sold.

Bleakley Financial Group first reported a position in DGX in Q4 2022 and held it in 10 quarters. The position peaked at $2.07M in Q1 2026. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Bleakley Financial Group reported no remaining Quest Diagnostics position as of Q2 2026 after selling out during the quarter.
  • Bleakley Financial Group sold 10,559 Quest Diagnostics shares in Q2 2026, an estimated $2.07M.
  • Bleakley Financial Group first reported a position in Quest Diagnostics in Q4 2022 and held it in 10 quarters.
  • Bleakley Financial Group's Quest Diagnostics position peaked at $2.07M in Q1 2026.
  • 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Bleakley Financial Group's 13F filing for Q2 2026, filed 5 Aug 2026.